Table 2.
Distribution of breast cancer tumor subtypes by race/ethnicity in the combined LACE and Pathways Studies (n = 2544)
| Tumor subtype | White n (%) | African American n (%) | Asian n (%) | Hispanic n (%) | Other n (%) | P valuea |
| Luminal A (ER+ and/or PR+, Her2-) n = 1868 (73.4) |
1464 (75.3) | 92 (59.4) | 135 (71.4) | 135 (68.5) | 37 (68.5) | 0.0001 |
| Luminal B (ER+ and/or PR+, Her2+) n = 294 (11.6) |
215 (11.1) | 14 (9.0) | 30 (15.9) | 28 (14.2) | 7 (13.0) | 0.18 |
| Triple negative (ER-, PR-, Her2-) n = 288 (11.3) |
204 (10.5) | 44 (28.4) | 12 (6.3) | 21 (10.7) | 7 (13.0) | < 0.0001 |
| Her2 overexpressing (ER-, PR-, Her2+) n = 94 (3.7) |
60 (3.1) | 5 (3.2) | 12 (6.4) | 13 (6.6) | 3 (5.5) | 0.03 |
| Total n = 2544 (100) | 1943 (100) | 155 (100) | 189 (100) | 197 (100) | 54 (100) | --- |
a From Pearson chi-square test across racial/ethnic categories.
ER = estrogen receptor; Her2 = human epidermal growth receptor 2; PR = progesterone receptor; + = positive; - = negative.